Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07620574 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

StatusEnrolling by Invitation
PhasePhase 3
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrolling by invitation only Study sites: 0 to 2 · Start date changed from estimate of May 31, 2026 to Jul 30, 2026 · Collaborators expanded, about 2 wordsv2 Show 3 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of May 31, 2026 to Jul 30, 2026
    • Collaborators expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
Prostate Cancer
2,487 trials monitored
See 160 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
and 2 more diseases
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
Trial Details
NCT Number NCT07620574
Lead Sponsor Exelixis
Collaborators: Bristol-Myers Squibb
Conditions Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC), Differentiated Thyroid Cancer (DTC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Colorectal Cancer +1 more
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov